#ExistRefRangeSet>
Reference Interval:
#ExistRefRangeTable> | Available Separately
| Components
| Reference Interval
| | No
| Saccharomyces cerevisiae Antibody (gASCA), IgG
| 0-44 Units: Negative 45-50 Units: Equivocal 51 Units or greater: Positive
| | No
| Laminaribioside Carbohydrate Antibody (ALCA), IgG
| 0-54 Units: Negative 55-60 Units: Equivocal 61 Units or greater: Positive
| | No
| Mannobioside Carbohydrate Antibody (AMCA), IgG
| 0-89 Units: Negative 90-100 Units: Equivocal 101 Units or greater: Positive
| | No
| Chitobioside Carbohydrate Antibody (ACCA), IgA
| 0-79 Units: Negative 80-90 Units: Equivocal 91 Units or greater: Positive
| | | | |
*ExistRefRangeTable>
|
*ExistRefRangeSet>
#ExistInterpDataSet>
| Interpretive Data: |
#ExistInterpData>If only one of the four markers in the Crohn Disease Prognostic Panel is positive, clinical specificity is at least 85 percent. If all four markers are negative and inflammatory bowel disease (IBD) is suspected, testing for ANCA by IFA is recommended to confirm or exclude the possibility of ulcerative colitis (UC).
See Compliance Statement A: www.aruplab.com/CS
*ExistInterpData>
|
*ExistInterpDataSet>
#ExistCPT>
| CPT Code(s): |
86671; 83516 x3
|
*ExistCPT>
#ExistCrossReferences>
Cross References: |
Glycan Antibodies (Crohn Disease Prognostic Panel), IBD Prognostic Panel (Crohn Disease Prognostic Panel), IBDX (Crohn Disease Prognostic Panel), Inflammatory Bowel Disease Prognostic Panel (Crohn Disease Prognostic Panel) |
*ExistCrossReferences>